Clinical trials: Large B-Cell Diffuse Lymphoma
Leukemia, Lymphoma
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00085449
- Testing
- alemtuzumab, cyclosporine, fludarabine phosphate
- Where
- 24 sites in United States
- Sponsor
- Alliance for Clinical Trials in Oncology
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
This phase I trial is studying the side effects and best dose of methoxyamine when given together with fludarabine phosphate in treating patients with relapsed or refractory hematologic malignancies.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01658319
- Testing
- fludarabine phosphate, methoxyamine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent Nervous System Lymphoma, Recurrent Primary Vitreoretinal DLBCL
Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma
This phase I trials studies side effects and best dose of pomalidomide when given together with nivolumab in treating patients with primary central nervous system diffuse large B cell lymphoma or primary vitreoretinal diffuse…
- Conditions
- Recurrent Nervous System Lymphoma, Recurrent Primary Vitreoretinal DLBCL, Refractory Nervous System Lymphoma, Refractory Primary Vitreoretinal DLBCL
- Trial name
- NCT03798314
- Testing
- Nivolumab, Pomalidomide
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Lymphoma
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Trial name
- NCT00670358
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
Diffuse Large B-Cell Lymphoma
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of…
- Trial name
- NCT07059650
- Testing
- DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR
- Where
- 13 sites in China
- Volunteers
- 150 people
- Sponsor
- Dizal Pharmaceuticals
Lymphoma
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004197
- Testing
- keyhole limpet hemocyanin, sargramostim, tumor cell-based vaccine therapy
- Where
- 2 sites in United States
- Sponsor
- University of Nebraska
Diffuse Large B Cell Lymphoma, Large-cell Lymphoma
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
Phase 1 study to assess the safety, preliminary efficacy of CD19 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose in subjects with diffuse large B-cell lymphoma (DLBCL).
- Conditions
- Diffuse Large B Cell Lymphoma, Large-cell Lymphoma, Lymphoma, B-Cell, Lymphoma
- Trial name
- NCT04052061
- Testing
- CD19 t-haNK
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Non-Hodgkin Lymphoma
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections).
- Trial name
- NCT05283720
- Testing
- Epcoritamab, Lenalidomide, Ibrutinib
- Where
- 76 sites in United States, China and 11 more
- Volunteers
- 264 people
- Sponsor
- Genmab
Burkitt Lymphoma, Lymphoma, Follicular
A Safety Study of SGN-CD19A for B-Cell Lymphoma
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
- Conditions
- Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
- Trial name
- NCT01786135
- Testing
- SGN-CD19A
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Seagen Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy…
- Conditions
- Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT05633615
- Testing
- Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography
- Where
- 95 sites in United States
- Volunteers
- 396 people
- Sponsor
- SWOG Cancer Research Network
Diffuse Large B-Cell Lymphoma
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
This is a prospective, multicenter, single-arm clinical study designed to evaluate the efficacy and safety of Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as salvage therapy for…
- Trial name
- NCT07001540
- Testing
- Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx)
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Diffuse Large B Cell Lymphoma
Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
This is a prospective, single-arm, open study to observe the efficacy and safety of the CART-SCB regimen (Clinical Regimen for the Prospective Study of Autologous Hematopoietic Stem Cell Boost for the Improvement of Bone Marrow…
- Trial name
- NCT06589089
- Testing
- autologous hematopoietic stem cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
Study of LUCAR-20S in Patients With R/R NHL
An open label, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large B-cell, follicular, mantle cell and small lymphocytic…
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT04176913
- Testing
- LUCAR-20S CAR-T cells
- Where
- 3 sites in China
- Volunteers
- 7 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
This study is aimed to explored the safety and efficacy of 7×19-THEMIS CAR-T cell therapy for large B-cell lymphoma and to conduct an exploratory comparison of the 3-month objective response rate (ORR) and complete remission rate…
- Conditions
- Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transforming Follicular Lymphoma (tFL)
- Trial name
- NCT07788118
- Testing
- 7×19-THEMIS CAR-T cells
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Lymphoma, Large B-Cell, Diffuse, Gene Expression Profiling
Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma
The purpose of the study is to investigate the proportion of the cell-of-origin (COO) subtypes in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with BTK inhibitor or lenalidomide and its biosimilars.
- Trial name
- NCT05318391
- Testing
- Gene expression profile
- Where
- China
- Volunteers
- 324 people
- Sponsor
- Shanghai Zhongshan Hospital
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
This phase II/III trial tests whether it is possible to decrease the chance of high-grade B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual combination of drugs used for treatment.
- Conditions
- Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT03984448
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 634 sites in United States
- Volunteers
- 363 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers.
- Conditions
- Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
- Trial name
- NCT07226843
- Testing
- LY4584180, Rituximab
- Where
- 46 sites in United States, France and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Lymphoma, Large-Cell, Diffuse
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent…
- Trial name
- ORCHARRD (NCT01014208)
- Testing
- OFATUMUMAB + DHAP, RITUXIMAB + DHAP
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 447 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.